Trupanion, Inc. has been making waves in the pet insurance industry with its Subscription Business segment, which offers monthly pet medical insurance subscriptions to cat and dog owners. As a result, the company’s shares have caught the attention of investors and analysts. Bloomberg Ratings reports that the eleven rating agencies that currently cover Trupanion have assigned it an average rating of “Moderate Buy.”
Among these ratings, an investment analyst issued a sell recommendation, a hold recommendation and four buy recommendations. Despite mixed opinions, the consensus among brokerages reporting on the stock over the past year is that Trupanion’s 12-month average price target is $72.11.
Nor have Trupanion’s successes gone unnoticed by hedge funds. Several of them have increased or reduced their stake in Trupanion shares in recent months. Institutional investors hold nearly 98% of the company’s shares.
Lindbrook Capital LLC saw significant growth in shares of Trupanion after increasing its position by 95.6% in the fourth quarter of last year; they now own more than half a thousand shares worth about $27,000. Greenhaven Road Investment Management LP, which bought shares for about $32,000, also saw positive results from its investment in the second quarter of last year.
Strs Ohio acquired a new position earlier this year at around $35,000 while Quadrant Capital Group LLC increased its stakes by 235.7% in the fourth quarter of 2020 to acquire nearly a thousand shares of current value of $45,000.
Finally, Harbor Investment Advisory LLC grew its holdings by 24.0% during the third quarter of last year to control more than one thousandth of all outstanding shares valued at $69,000 today.
With such diverse opinions among experts and fluctuating levels of hedge fund investment, it ultimately begs the question: should potential buyers heed these ratings and increase their own stakes in Trupanion, or remain cautious and wait until better news? It remains to be seen how the company will fare in the coming months.
Mixed analyst ratings and insider selling trends are raising uncertainty about Trupanion’s future prospects.
Trupanion, Inc. (NASDAQ:TRUP) recently made headlines as several stock analysts weighed in on the company. Piper Sandler raised its price target on Trupanion shares from $53.00 to $63.00, while Lake Street Capital raised its target price on Trupanion shares from $67.00 to $75.00 and Evercore ISI lowered its target price from $68.00 to $59.00. Canaccord Genuity Group also took a bullish stance by raising its target price on Trupanion shares from $66.00 to $72.00 and giving the stock a “buy” rating.
However, not all analysts were so optimistic about Trupanion’s future prospects as StockNews.com assumed a hedge and issued a “sell” rating on the stock.
Insiders also sold shares of Trupanion, with director Michael Doak selling 700 shares of the company in two transactions for a total value of more than $32,000, while CEO Darryl Rawlings sold 4,000 shares worth over $220,000 in March.
Despite these mixed signals, Trupanion remains focused on its core business, medical insurance for cats and dogs, through its Subscription Business segment, which offers monthly subscriptions to medical insurance for pets, while that its Others Business segment caters to companies or organizations that choose to provide medical insurance for cats. and dogs as an added bonus.
Trupanion had announced its quarterly earnings data showing a beating of estimates with revenue up 26.6% from the same quarter last year despite net margins and negative returns on equity.
With a market capitalization of over $1 billion, Trupanion continues to hold growth potential in the booming pet care industry, but investors should proceed with caution given mixed analyst ratings and insider selling trends in volatile market conditions where even the most optimistic ratings could change. at any moment.